NOVATO, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: NASDAQ:), a biopharmaceutical firm targeted on the event and commercialization of novel therapies for uncommon and ultrarare illnesses, as we speak reported the grant of 37,975 restricted inventory models of the corporate’s frequent inventory to 12 newly employed non-executive officers of the corporate. The awards have been authorized by the compensation committee of the corporate’s board of administrators and granted underneath the Ultragenyx Employment Inducement Plan, with a grant date of August 16, 2024, as an inducement materials to the brand new staff getting into into employment with Ultragenyx in accordance with Nasdaq Itemizing Rule 5635(c)(4).
The restricted inventory models vest over 4 years, with 25% of the underlying shares vesting on every anniversary of the grant date, topic to the worker being repeatedly employed by the corporate as of such vesting dates.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical firm dedicated to bringing novel merchandise to sufferers for the remedy of great uncommon and ultrarare genetic illnesses. The corporate has constructed a various portfolio of authorized therapies and product candidates geared toward addressing illnesses with excessive unmet medical want and clear biology for remedy, for which there are usually no authorized therapies treating the underlying illness.
The corporate is led by a administration crew skilled within the growth and commercialization of uncommon illness therapeutics. Ultragenyx’s technique relies upon time- and cost-efficient drug growth, with the purpose of delivering protected and efficient therapies to sufferers with the utmost urgency.
For extra info on Ultragenyx, please go to the corporate’s web site at: www.ultragenyx.com.
Contact Ultragenyx
Traders & Media
Joshua Higa
(415) 475-6370
